Elevation Oncology, Inc..
ELEV.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of selective cancer therapies to treat patients with genomically defined cancers. The company's lead product candidate is seribantumab, an anti-HER3 IgG1 antibody that binds to HER3, inhib...Show More
Better Health for All
0
Elevation Oncology is a clinical-stage biopharmaceutical company focused on developing cancer therapies. Its entire business is devoted to health improvement through the discovery and development of selective cancer therapies. The lead product candidate, EO-3021, is in Phase 1 clinical trials for claudin 18.2-expressing gastric or GEJ cancer, showing an objective response rate (ORR) of 42.8% and a disease control rate (DCR) of 71.4% in a biomarker-enriched patient subset.
1
The FDA granted fast track designation to EO-3021.
2
The company does not generate revenue from products with established negative health outcomes. In terms of safety, EO-3021 was generally well-tolerated in 32 patients, with no Grade 4 or 5 treatment-related toxicities.
3
However, four dose-limiting toxicities (DLTs) were observed at the 2.9 mg/kg dose level, including Grade 3 fatigue and encephalopathy, leading to the selection of lower doses (2.0 mg/kg and 2.5 mg/kg) for further exploration.
4
The company's R&D expenses were $28.6 million for the full year 2024, reflecting investment in clinical trials and pipeline programs.
5
There is no specific information regarding the ethical conduct of clinical trials beyond the general reporting of safety and efficacy data.
Fair Money & Economic Opportunity
0
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company focused on cancer therapies.
1
The provided articles contain no evidence that the company offers lending, deposit, or other financial services to consumers. Therefore, all Key Performance Indicators related to 'Fair Money & Economic Opportunity', which are designed for financial institutions, are not applicable to Elevation Oncology.
Fair Pay & Worker Respect
0
The provided articles do not contain specific, quantitative data points for any of the Fair Pay & Worker Respect KPIs. While articles mention workforce reductions (70% in March 2025 and 30% in 2022), these refer to company-initiated reductions, not voluntary employee turnover as defined by the 'turnover_rate' KPI.
1
Employee ratings on Glassdoor are provided for aspects like culture and compensation, but these are not a formal 'worker_engagement_score' or index as required by the rubric, and the article explicitly states 'No data available' for this KPI.
2
For all other KPIs, the articles either explicitly state that no data is available or do not provide any relevant information.
Fair Trade & Ethical Sourcing
0
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company focused on cancer therapy development.
1
The nature of its business, which involves research and development of pharmaceuticals, indicates that it does not procure or trade physical commodities, nor does it have a supplier base or supply chain tiers that typically require fair-trade certifications, welfare/sourcing audits, or expose it to upstream labor practices related to child/forced labor or high-risk materials. Therefore, the company falls under the 'N/A' category for several KPIs within the Fair Trade & Ethical Sourcing value, as these metrics are not applicable to its operational model.
Honest & Fair Business
-60
Elevation Oncology has a formal whistleblower policy that includes procedures for confidential anonymous submissions by employees regarding accounting, internal controls, or auditing matters.
1
A third-party hosted hotline (EthicsPoint) is available via website and telephone for anonymous reporting of suspected policy violations.
2
The company also has an anti-corruption policy emphasizing compliance with the Foreign Corrupt Practices Act (FCPA).
3
However, there is no evidence of independent investigation processes for whistleblower reports, nor is there information on the frequency or effectiveness of anti-corruption training. The third-party verification of ethical claims is limited to the whistleblower hotline process, with no evidence of broader independent verification.
Kind to Animals
0
No specific evidence was found in the provided articles regarding Elevation Oncology, Inc.'s direct actions, policies, or performance related to animal welfare, animal testing, or animal-free alternatives. The articles primarily discuss general industry trends, regulatory changes, and the adoption of New Approach Methodologies (NAMs) in preclinical drug development by various regulatory bodies and research initiatives, rather than detailing the company's specific practices or commitments.
No War, No Weapons
0
No evidence was found in the provided articles to assess Elevation Oncology, Inc. against the 'No War, No Weapons' ethical value. The articles primarily detail financial performance and corporate governance for Elevation Oncology, Inc. One article discusses a conflict minerals policy, but it pertains to a different company (RF-Lambda) and is therefore not applicable.
1
There is no information regarding revenue from arms contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other metric relevant to this ethical value for Elevation Oncology, Inc.
Planet-Friendly Business
0
No relevant data was found in the provided articles to assess Elevation Oncology, Inc. against the 'Planet-Friendly Business' ethical value.
1
Both articles indicated a 'page not found' error, preventing any data extraction for any KPI.
2
Respect for Cultures & Communities
0
No specific, factual evidence was found in the provided articles regarding Elevation Oncology's performance on any of the KPIs related to 'Respect for Cultures & Communities'. The articles primarily focus on clinical trial results, financial performance, investor relations, and general career information. While one article discusses a policy summit on diversity, equity, and inclusion in cancer care, it does not provide company-specific data for Elevation Oncology.
1
Safe & Smart Tech
0
No information regarding Elevation Oncology, Inc. (ELEV.US) was found in the provided articles. The articles discuss data breaches and cybersecurity incidents related to other entities such as Integrated Oncology Network (ION), University of Vermont Health Network (UVMHN), and Infosys McCamish Systems (IMS). Therefore, no assessment can be made for any of the Safe & Smart Tech KPIs for ELEV.US.
Zero Waste & Sustainable Products
0
The provided articles, primarily investor relations documents and financial reports for Elevation Oncology, Inc., focus on the company's financial performance, clinical trial progress, and drug development milestones. Several articles also discuss the environmental impact of external beam radiation therapy (EBRT), which is a medical treatment, not directly related to Elevation Oncology's product lifecycle or operational waste management. No information or specific data points are available regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
Therefore, no KPIs under the 'Zero Waste & Sustainable Products' value can be scored based on the provided evidence.